Evotec SE EVO
Annual
Quarterly
No annual revenue total was found in Evotec SE's SEC filings.
Evotec SE (EVO) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue
—
Net income
—
Operating cash flow
—
Free cash flow
—
EPS
—
Dividend per share
None
Shares outstanding
177.78M
+0.1% vs prior year
Net cash
—
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- EVO (Nasdaq), EVOTF (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- Germany
- Headquarters
- Hamburg
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1412558
- Former names
- Evotec AG (until Sep 23, 2021)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 6-K | Current report (foreign issuer) | Nov 5, 2026 | Nov 5, 2026 |
| 6-K | Current report (foreign issuer) | Oct 15, 2026 | Oct 15, 2026 |
| 6-K | Current report (foreign issuer) | Oct 14, 2026 | Oct 14, 2026 |
| 6-K | Current report (foreign issuer) | Sep 29, 2026 | Sep 29, 2026 |
| 6-K | Current report (foreign issuer) | Sep 9, 2026 | Sep 9, 2026 |
| 6-K | Current report (foreign issuer) | Aug 13, 2026 | Aug 13, 2026 |
Source: SEC EDGAR filings. This is company-reported data, not investment advice.